TDAC agrees to $50 million share sale to Naetas tied to ProLogium merger
Translational Development Acquisition Corp. (TDAC) entered a subscription agreement under which Naetas Holding Limited will buy 5,000,000 TDAC Class A ordinary shares at $10.00 each, for $50,000,000, and receive 5,000,000 warrants at no additional consideration. The purchase is tied to the closing of TDAC's business combination with ProLogium Holding Inc., and the closing is contingent on that combination being completed, so shareholders would see new shares and warrants issued only if the merger proceeds.
Key points
- Subscriber: Naetas Holding Limited, an institutional accredited investor, purchasing 5,000,000 Class A ordinary shares at $10.00 per share for $50,000,000
- Subscribed Warrants: 5,000,000, exercisable at $11.50 per share, with a $18.00 redemption trigger and $0.01 redemption price
- Closing expected one business day before the first merger; the subscription terminates if the Business Combination Agreement is validly terminated or the Termination Date passes without closing
- ProLogium to file a resale registration statement within 45 calendar days after the Business Combination closes, after the Form F-4 is declared effective
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.